Dr. Mehta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
202 S Greenleaf Ave Suite E
Cancer Treatment Centers of America
Gurnee, IL 60031Phone+1 800-322-9183Fax+1 847-336-7566
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 1990 - 1992
- Louis A Weiss Memorial HospitalResidency, Internal Medicine, 1987 - 1990
- Baroda Medical CollegeClass of 1982
Certifications & Licensure
- AZ State Medical License 2021 - 2027
- FL State Medical License 2017 - 2026
- IL State Medical License 1987 - 2026
- IN State Medical License 2005 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- 228 citationsOverall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase ...Giorgio V. Scagliotti, Vera Hirsh, Salvatore Siena, David H. Henry, Penella J. Woll
Journal of Thoracic Oncology. 2012-12-01 - 67 citationsCombination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic MelanomaJon M. Richards, Danielle Gale, Nilesh Mehta, Timothy Lestingi
Journal of Clinical Oncology. 1999-02-01 - 29 citationsAn open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.Allen Lee Cohn, Grace C. Shumaker, Pankaj Khandelwal, David Smith, Marcus A. Neubauer
Clinical Colorectal Cancer. 2011-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: